Literature DB >> 18234910

Identification of transcriptional regulatory elements in the human somatostatin receptor sst2 promoter and regions including estrogen response element half-site for estrogen activation.

Nobuko Kimura1, Nobuko Takamatsu, Yoshio Yaoita, R Yoshiyuki Osamura, Narimichi Kimura.   

Abstract

The somatostatin receptor subtype 2 (sst2) mediates inhibition of hormone secretion and cell proliferation, and modulates neurotransmission. Its expression is widespread in various normal tissues and many malignant cells, and is up-regulated by estrogen in breast cancer cells. This study was undertaken to investigate molecular mechanism of transcriptional regulation of the human sst2 gene, for which an additional exon (exon 1) in the 5'-untranslated region was recently found. Transient transfection and mutational analysis showed that the immediate 5'-upstream region containing two Sp1 (-54/-45 and -88/-79) and an ATF/CRE (-69/-62) sites provided full promoter activity. An EMSA together with transfection analysis in Sp1-deficient Drosophila Schneider line (SL2) cells showed that Sp1 acted on the proximal Sp1 site, whereas Sp3, Sp1, and Sp2 did on the distal Sp1 site. Activating transcription factor-2 (ATF)-2, c-Jun, and cyclic AMP response element-binding protein (CREB) interacted with the ATF/CRE site. Transcriptional activation by estrogen occurred through two different regions; one included these proximal elements and the other existed in the upstream region containing estrogen response element (ERE) half-site (-348/-344) and GC-rich sequence (-447/-414). This upstream estrogen responsiveness was observed in a human breast cancer T47D cell, but not in GH(3) or estrogen receptor alpha (ERalpha) -expressing HeLa cells, and was potentiated by overexpression of ERalpha or ERbeta, whose binding to the ERE half-site was verified by EMSAs. A chromatin immunoprecipitation assay suggested that ERalpha was recruited to the ERE half-site after estrogen treatment in T47D cells. The present results should provide a molecular basis for transcriptional regulation in a variety of physiological and pathological contexts of sst2-expressing tissues.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18234910     DOI: 10.1677/JME-07-0108

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  8 in total

1.  Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Peng Guo; Xiaodong Sun; Qunna Li; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2011-03-02       Impact factor: 5.157

2.  Fibroblast growth factor 9 (FGF9)-pituitary homeobox 2 (PITX2) pathway mediates transforming growth factor β (TGFβ) signaling to regulate cell proliferation in palatal mesenchyme during mouse palatogenesis.

Authors:  Jun-ichi Iwata; Lily Tung; Mark Urata; Joseph G Hacia; Richard Pelikan; Akiko Suzuki; Liza Ramenzoni; Obaid Chaudhry; Carolina Parada; Pedro A Sanchez-Lara; Yang Chai
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

3.  Multiple sequence-specific DNA-binding proteins mediate estrogen receptor signaling through a tethering pathway.

Authors:  Nina Heldring; Gary D Isaacs; Adam G Diehl; Miao Sun; Edwin Cheung; Jeffrey A Ranish; W Lee Kraus
Journal:  Mol Endocrinol       Date:  2011-02-17

Review 4.  Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.

Authors:  Samuel Adant; Girish M Shah; Jean-Mathieu Beauregard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-06       Impact factor: 9.236

5.  Prioritization of epilepsy associated candidate genes by convergent analysis.

Authors:  Peilin Jia; Jeffrey M Ewers; Zhongming Zhao
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

6.  Lumiestrone is Photochemically Derived from Estrone and may be Released to the Environment without Detection.

Authors:  Vance L Trudeau; Belinda Heyne; Jules M Blais; Fabio Temussi; Susanna K Atkinson; Farzad Pakdel; Jason T Popesku; Vicki L Marlatt; Juan C Scaiano; Lucio Previtera; David R S Lean
Journal:  Front Endocrinol (Lausanne)       Date:  2011-12-02       Impact factor: 5.555

7.  Gonadotroph Tumors Show Subtype Differences That Might Have Implications for Therapy.

Authors:  Mirela Diana Ilie; Alexandre Vasiljevic; Camille Louvet; Emmanuel Jouanneau; Gérald Raverot
Journal:  Cancers (Basel)       Date:  2020-04-20       Impact factor: 6.639

8.  Cyclooxygenase-2 up-regulates hepatic somatostatin receptor 2 expression.

Authors:  Yao-Yao Lu; Jin-Hang Gao; Chong Zhao; Shi-Lei Wen; Cheng-Wei Tang; Yu-Fang Wang
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.